The Unidirectional Hypoxia-Activated Prodrug OCT1002 Inhibits Growth and Vascular Development in Castrate-Resistant Prostate Tumors

Prostate - United States
doi 10.1002/pros.23434
Full Text
Abstract

Available in full text

Categories
OncologyUrology
Date
Authors
Publisher

Wiley

Related search

New Therapeutics to Treat Castrate-Resistant Prostate Cancer

The Scientific World Journal
BiochemistryMedicineGeneticsMolecular BiologyEnvironmental Science
2013English

Guidelines for the Management of Castrate-Resistant Prostate Cancer

Journal of the Canadian Urological Association
OncologyUrology
2010English

Guidelines for the Management of Castrate-Resistant Prostate Cancer

Canadian Urological Association Journal
Urology
2013English

Current Options and Future Directions in Castrate Resistant Prostate (CRPC)

2011English

Crosstalk Between the Androgen Receptor and -Catenin in Castrate-Resistant Prostate Cancer

Cancer Research
Cancer ResearchOncology
2008English

Management of Docetaxel Failures in Metastatic Castrate-Resistant Prostate Cancer

Urologic Clinics of North America
Urology
2012English

Current Perspectives on Bone Metastases in Castrate-Resistant Prostate Cancer

Cancer and Metastasis Reviews
Cancer ResearchOncology
2018English

The Transcription Factor CUX1 Negatively Regulates Invasion in Castrate Resistant Prostate Cancer

Oncotarget
Oncology
2020English

Evidence for the Efficacy of Enzalutamide in Postchemotherapy Metastatic Castrate-Resistant Prostate Cancer

Therapeutic Advances in Urology
Urology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy